Effect of Short Term Atorvastatin Treatment,80mg/Day on Early Regression of Carotid Artery Atherosclerotic Lesions (DCAT)
Primary Purpose
Atherosclerosis
Status
Unknown status
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Atorvastatin
Sponsored by

About this trial
This is an interventional treatment trial for Atherosclerosis focused on measuring Atherogenesis, Atheroma, Arteriosclerosis
Eligibility Criteria
Inclusion Criteria:
- Men or women
- >18 yrs old
- Expected to have an endarterectomy on each carotid artery
- No contraindications for atorvastatin
- Stable cardiovascular health
- Lipid lowering treatment less than 6 mo duration
- Diabetic included if diabetes is controlled
- Patient is not claustrophobic
- Patient has evaluable carotid plaques.
Exclusion Criteria:
- Patient has had previous carotid endarterectomy,stenting, or other procedure
- Unstable cardiovascular status
- Hypersensitivity to statin therapy
- Neck anatomy preventing acquiring bilateral evaluable plaques
- Weight over 285 lbs.
Sites / Locations
- Baylor College of MedicineRecruiting
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
A
Arm Description
An untreated carotid plaque will be obtained at the first endarterectomy. Atorvastatin 80mg will be administered for 3 months. The contralateral (treated) plaque will be obtained at the second endarterectomy. Hence, each patient will be his/her own control
Outcomes
Primary Outcome Measures
Changes in carotid plaque composition as assessed by MRI and histology
Secondary Outcome Measures
Changes content of cells, proteins and genes in carotid plaque
Changes in content of selected proteins and their encoding genes in carotid plaques
Full Information
NCT ID
NCT00640744
First Posted
January 2, 2008
Last Updated
December 2, 2010
Sponsor
Baylor College of Medicine
Collaborators
Pfizer
1. Study Identification
Unique Protocol Identification Number
NCT00640744
Brief Title
Effect of Short Term Atorvastatin Treatment,80mg/Day on Early Regression of Carotid Artery Atherosclerotic Lesions
Acronym
DCAT
Official Title
Phase 3 Study of Atorvastatin Effects on Carotid Atherosclerosis
Study Type
Interventional
2. Study Status
Record Verification Date
December 2010
Overall Recruitment Status
Unknown status
Study Start Date
February 2006 (undefined)
Primary Completion Date
November 2009 (Anticipated)
Study Completion Date
February 2010 (Anticipated)
3. Sponsor/Collaborators
Name of the Sponsor
Baylor College of Medicine
Collaborators
Pfizer
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Atherosclerosis is a disease in which the blood vessels become blocked by plaques (consisting of fat, calcification, and fibrous tissue), reducing blood flow to vital organs and tissues.Blockage of the carotid arteries in the neck is a major cause of stroke. One way of treating carotid atherosclerosis is with cholesterol-lowering drugs called statins. Statins have been shown to reduce the risk of coronary heart disease by 24-40% and risk pf stroke by 11-30%.The purpose of this study is to determine if short term treatment with atorvastatin causes early favorable changes in the plaques that block blood flow through the carotid arteries. These changes can be assessed 1) by taking pictures of the carotid arteries with MRI and Ultrasound before and after statin treatment, and 2) by special studies of the plaques removed from the carotid arteries by surgery.
Detailed Description
Candidates for bilateral carotid endarterectomy (CEA) who meet study criteria will provide informed consent before their randomization. Before the first CEA, the patient will have MRI, US, and EBCT exams of both carotids. The most occlusive plaque will be resected at the first CEA. The patient will then receive atorvastatin 80 mg/day for 3 months. Then the second CEA will be performed. Six weeks after the second CEA, the patient will have another MRI, US, and EBCT exam and at 6, 12, and 18 months thereafter. This protocol will allow comparison of the characteristics of the plaque that has been exposed to drug vs the plaque that has not been exposed. It will also allow monitoring the effect of drug on restenosis after surgery.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Atherosclerosis
Keywords
Atherogenesis, Atheroma, Arteriosclerosis
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
12 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
A
Arm Type
Other
Arm Description
An untreated carotid plaque will be obtained at the first endarterectomy. Atorvastatin 80mg will be administered for 3 months. The contralateral (treated) plaque will be obtained at the second endarterectomy. Hence, each patient will be his/her own control
Intervention Type
Drug
Intervention Name(s)
Atorvastatin
Intervention Description
Atorvastatin 80 mg tablet/day for 3 months
Primary Outcome Measure Information:
Title
Changes in carotid plaque composition as assessed by MRI and histology
Time Frame
3 months
Secondary Outcome Measure Information:
Title
Changes content of cells, proteins and genes in carotid plaque
Time Frame
3 months
Title
Changes in content of selected proteins and their encoding genes in carotid plaques
Time Frame
3 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Men or women
>18 yrs old
Expected to have an endarterectomy on each carotid artery
No contraindications for atorvastatin
Stable cardiovascular health
Lipid lowering treatment less than 6 mo duration
Diabetic included if diabetes is controlled
Patient is not claustrophobic
Patient has evaluable carotid plaques.
Exclusion Criteria:
Patient has had previous carotid endarterectomy,stenting, or other procedure
Unstable cardiovascular status
Hypersensitivity to statin therapy
Neck anatomy preventing acquiring bilateral evaluable plaques
Weight over 285 lbs.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
William Insull, M.D.
Phone
713-798-4128
Email
winsull@bcm.tmc.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Addison Taylor, MD/PhD
Phone
713-798-4721
Email
ataylor@bcm.tmc.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Joel D Morrisett, PhD
Organizational Affiliation
Baylor College of Medicine
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Addison M Taylor, MD, PhD
Organizational Affiliation
Baylor College of Medicine
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
William Insull, MD
Organizational Affiliation
Baylor College of Medicine
Official's Role
Study Chair
Facility Information:
Facility Name
Baylor College of Medicine
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Joel D Morrisett, PhD
Phone
713-798-4164
Email
morriset@bcm.tmc.edu
First Name & Middle Initial & Last Name & Degree
Addison Taylor, MD/PhD
Phone
713-798-4721
Email
ataylor@bcm.tmc.edu
First Name & Middle Initial & Last Name & Degree
Joel D Morrisett, PhD
12. IPD Sharing Statement
Citations:
PubMed Identifier
16888239
Citation
Choudhary S, Higgins CL, Chen IY, Reardon M, Lawrie G, Vick GW 3rd, Karmonik C, Via DP, Morrisett JD. Quantitation and localization of matrix metalloproteinases and their inhibitors in human carotid endarterectomy tissues. Arterioscler Thromb Vasc Biol. 2006 Oct;26(10):2351-8. doi: 10.1161/01.ATV.0000239461.87113.0b. Epub 2006 Aug 3.
Results Reference
background
Links:
URL
http://www.bcm.edu/medicine/athero
Description
Atherosclerosis and Vascular Biology Research Training Program
Learn more about this trial
Effect of Short Term Atorvastatin Treatment,80mg/Day on Early Regression of Carotid Artery Atherosclerotic Lesions
We'll reach out to this number within 24 hrs